Your browser doesn't support javascript.
loading
CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease.
Kosovec, Juliann E; Zaidi, Ali H; Omstead, Ashten N; Matsui, Daisuke; Biedka, Mark J; Cox, Erin J; Campbell, Patrick T; Biederman, Robert W W; Kelly, Ronan J; Jobe, Blair A.
Afiliação
  • Kosovec JE; Esophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA.
  • Zaidi AH; Esophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA.
  • Omstead AN; Esophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA.
  • Matsui D; Department of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
  • Biedka MJ; Esophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA.
  • Cox EJ; Esophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA.
  • Campbell PT; Esophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA.
  • Biederman RWW; McGinnis Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, USA.
  • Kelly RJ; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA.
  • Jobe BA; Esophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA.
Oncotarget ; 8(59): 100421-100432, 2017 Nov 21.
Article em En | MEDLINE | ID: mdl-29245989
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Risk_factors_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Risk_factors_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article